Corporate History

1975/05	DOMS-IATRON Co., Ltd. (currently Kainos) was established with a capital stock of 30,000,000 yen as a developer of new products in the health care industry.
1975/07	Changed its name to Kainos Laboratories, Inc.
1975/09	Released the world's first enzyme-based serum transaminase measurement reagent kit.
1976/12	Formed a technical tie-up with Mitsui Pharmaceutical Industry Co. (Currently Bayer Yakuhin,Ltd.) on enzyme immunoassay method (EIA).
1981/04	Entered into a technical tie-up agreement with Hitachi Chemical Co., Ltd.(Currently Hitachi Chemical Diagnostics Systems Co., Ltd.) on reagents for clinical analysis equipment.
1983/03	Entered into a sales agreement for blood transfusion diagnostics products with GAMMA BIOLOGICALS, Inc (USA)
1983/04	Released an enzyme-based creatinine measurement reagent kit.
1987/06	Entered into a technical tie-up agreement with Nippon Kayaku Co., Ltd. on clinical examination reagents.
1992/09	Entered into a technical tie-up agreement with Kirin Beer Co., Ltd. (Currently Kyowa Kirin Co., Ltd.) on clinical examination reagents.
1993/08	Moved production to Kasama Factory, and began production of biochemical and immunoserological reagents.
1993/10	Entered into a technical tie-up agreement with Asahi Chemical Industry Co., Ltd. (Currently Asahi Kasei Pharma Corporation) on clinical examination reagents.
1995/10	Moved the Head Office to Hongo, Bunkyo-ku, Tokyo.
1995/12	Listed on JASDAQ.
2000/06	Acquired ISO 9001 certification, an international standard for quality assurance.
2000/08	Entered into the licence agreement of NASBA Patents with Organon Teknika B. V. (Ownership of the "NASBA Gene Amplification" patent has been transferred from Organon Teknika B.V. to bioMerieux.)
2004/05	Entered into a distributorship agreement for genetic products with bioMerieux Japan.
2004/11	Launched marketing of an influenza detection reagent "Statmark™ Influenza A/B" that had been jointly developed by Nichirei Corporation (currently Nichirei Bioscience Inc,) and Kainos.
2005/07	Created Kainos BB, Co. Ltd. by spinning out Kainos' Blood Banking business (in June 2005) then changed the name of the spun out company to Immucor-Kainos, Inc. through a joint venture agreement established as a part of the ongoing collaborative effort between Immucor, Inc. and Kainos.
2006/05	Acquired ISO 13485 certification, an international standard for quality assurance of in vitro medical equipment.
2007/10	Entered into a technical tie-up agreement with Sysmex Corporation on reagents for medical device.
2008/04	Introduction of the Kainos Executive Office System. Established Compliance Center.
2008/05	Kainos-Immucor, Inc.'s (currently K. K. Immucor) stocks were transferred to Immucor, Inc.
2011/09	Entered into a distributorship agreement for blood transfusion diagnostics products with Grifols SA.
2018/02	Insurance coverage granted to the assays respectively measuring two fractions of blood carnitine using blood carmitine measuring reagents based on the enzyme cycling method.
2018/04	Insurance coverage granted to the diagnostic drug based on an ADAMTS13 activity measurement reagent for the thrombotic thrombocytopenic purpura.
2019/05	Concluded a share transfer agreement with Asahi Kasei Pharma Corporation to further enhance the mutual business relationship.
2020/09	Capital tie-up with Gene Therapy Research Institution Co.,Ltd. by accepting a part of its third-party allotment of shares.
2022/02	Concluded a capital and business tie-up with Sysmex Corporation to further enhance the mutual business relationship.